MetLife Investment Management’s Aclaris Therapeutics ACRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $80K | Buy |
+56,344
| New | +$80K | ﹤0.01% | 2644 |
|
|
2023
Q4 | – | Sell |
-35,160
| Closed | -$241K | – | 2825 |
|
|
2023
Q3 | $241K | Hold |
35,160
| – | – | ﹤0.01% | 2094 |
|
|
2023
Q2 | $365K | Buy |
35,160
+1,261
| +4% | +$13.1K | ﹤0.01% | 1899 |
|
|
2023
Q1 | $274K | Hold |
33,899
| – | – | ﹤0.01% | 2024 |
|
|
2022
Q4 | $534K | Buy |
33,899
+2,628
| +8% | +$41.4K | ﹤0.01% | 1603 |
|
|
2022
Q3 | $492K | Hold |
31,271
| – | – | ﹤0.01% | 1644 |
|
|
2022
Q2 | $437K | Buy |
31,271
+4,989
| +19% | +$69.6K | ﹤0.01% | 1762 |
|
|
2022
Q1 | $453K | Buy |
26,282
+9,700
| +58% | +$167K | ﹤0.01% | 1835 |
|
|
2021
Q4 | $241K | Hold |
16,582
| – | – | ﹤0.01% | 1944 |
|
|
2021
Q3 | $298K | Hold |
16,582
| – | – | ﹤0.01% | 1825 |
|
|
2021
Q2 | $291K | Buy |
+16,582
| New | +$291K | ﹤0.01% | 1914 |
|
|
2019
Q1 | – | Sell |
-13,157
| Closed | -$97.2K | – | 2569 |
|
|
2018
Q4 | $97.2K | Hold |
13,157
| – | – | ﹤0.01% | 2305 |
|
|
2018
Q3 | $191K | Hold |
13,157
| – | – | ﹤0.01% | 2111 |
|
|
2018
Q2 | $263K | Buy |
13,157
+3,244
| +33% | +$64.8K | ﹤0.01% | 1782 |
|
|
2018
Q1 | $174K | Hold |
9,913
| – | – | ﹤0.01% | 1955 |
|
|
2017
Q4 | $244K | Buy |
+9,913
| New | +$244K | ﹤0.01% | 1824 |
|